已收盤 11-09 16:00:00 美东时间
0.000
0.00%
11月21日,Achieve Life Sciences Inc. Common Shares(ACHV)收平,报6.78美元,成交额729.55万美元,市值...
11-21 06:53
Achieve Life Sciences (NASDAQ:ACHV) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.20) by 45 percent. This is a 60.71 percent increase over losses of $(0.28) per share from the same period last year.
11-10 21:31
AchieveRx, The Quit Company (Nasdaq: QUIT), announced its third-quarter 2026 financial results and updates, including the launch of its new corporate brand identity, the presentation of 52-week ORCA-OL trial data showing increased quit rates for smokers, the expansion of its leadership team, and the completion of three commercial-scale stability batches for U.S.-based manufacturing. The company reported $201.5 million in cash, cash equivalents, a...
11-10 13:00
11月10日,Achieve Life Sciences Inc. Common Shares(ACHV)收涨0.89%,报6.78美元,成交额729.55万美...
11-10 06:56
Achieve Life Sciences, Inc. announced the approval of stock option grants and RSU awards totaling 97,000 shares each for three new employees. The stock options have a four-year vesting period, with 25% vesting after the first year and the remaining 75% vesting monthly over the next three years. RSUs also vest over four years, with 25% vesting annually. Both awards are under the 2024 Equity Inducement Plan and align with Nasdaq Listing Rule 5635(c...
11-02 13:30
10月30日,Achieve Life Sciences Inc. Common Shares(ACHV)收涨4.96%,报7.19美元,成交额978.21万美...
10-30 05:54
10月22日,Achieve Life Sciences Inc. Common Shares(ACHV)收平,报6.51美元,成交额1616.18万美元,市值...
10-22 06:00
Achieve Life Sciences announced positive results from its 52-week ORCA-OL trial of cytisinicline for smoking and vaping cessation. Among 479 participants, 31.2% quit smoking or vaping by the end of the year, with quit rates rising throughout the trial. Participants were hard-to-treat, having failed prior quit attempts and often with chronic conditions. Cytisinicline was generally well-tolerated, with no significant safety concerns. The study high...
10-21 12:30
Lisata Therapeutics announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026. Farrow, a veteran biopharma CFO with over 15 years of experience, will also serve on the Audit Committee. His expertise in financial leadership and successful commercial launches will support Lisata's Phase 2b programs for severe hypertriglyceridemia and acromegaly. Farrow currently serves as CFO and Chief Strategy Officer of Tar...
10-14 20:05
今日重点评级关注:Ascendiant Capital:维持Aytu BioPharma"买入"评级,目标价从14.5美元升至15美元;摩根大通:维持Annexon"超配"评级,目标价从14美元升至15美元
10-01 19:18